-
Researchers from
@MIPS_Australia at@MonashPharm and the team at@MonashBDI have granted exclusive license of a new polymyxin antibiotic to#Qpexbiopharma to tackle the new wave of#superbugs. More on the website nowhttps://www.monash.edu/pharm/about/news/news-listing/2018/us-biopharmaceutical-company-licenses-monash-university-superbug-drug-discovery … -
Don't miss
@CHARM_UCSD Colloquium Tuesday to launch the new decade: Victor Torres NYU (@TorresVJ_Lab) on innovative MRSA therapeutics, Manuela Raffatellu (@mraffatellu) on new treatments inspired by bacterial competition, and Mike Dudley on the exciting pipeline at#QPexBioPharma pic.twitter.com/UrwlOiApJO
-
Congratulations to
@MikeMndudley – formerly of@MDCONews – on starting#QpexBiopharma! Looking forward to your presentation at#AMRCongressUSA this weekpic.twitter.com/3mZnnAVW60
-
Congrats to
#QpexBiopharma, who announced today a collaboration with Brii Biosciences to develop and commercialize antibiotics for drug-resistant infections in China! Qpex CEO Michael Dudley will be speaking at the#WorldAMRCongress — learn more here:https://www.prnewswire.com/news-releases/qpex-biopharma-and-brii-biosciences-enter-into-a-strategic-collaboration-to-develop-and-commercialize-antibiotics-for-drug-resistant-infections-in-china-300942653.html …
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.